http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
-
Arrowhead Pharma (ARWR) Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting
-
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
-
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
-
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
-
Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
-
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Filing for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
-
Arrowhead Pharmaceuticals Corp (ARWR) to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD
-
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
-
Arrowhead (ARWR) Announces $3.7 Billion License and Collaboration Agreements with Janssen (JNJ)
-
Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
-
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
-
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Corp (ARWR) to Present Positive ARO-HBV Clinical Data Demonstrating HBsAg Reductions
-
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
-
Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) Reports $10 Million Milestone Payment from Amgen
-
Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results
-
Arrowhead Pharmaceuticals Corp (ARWR) Highlights New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
-
Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
-
Arrowhead Pharmaceuticals Corp (ARWR) Granted Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
-
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
-
Arrowhead Pharmaceuticals Corp (ARWR) Announces Complete Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
-
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
-
Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
-
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
-
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
-
Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
-
Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
-
Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
-
Arrowhead Pharmaceuticals Corp (ARWR) Announces Clinical Data on ARC-520 at International Liver Congress 2018
-
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
-
Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress
-
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
-
Arrowhead Pharmaceuticals Corp (ARWR) Commences Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
-
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

